1. Market Research
  2. > CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review

CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CEL-SCI Corporation (CEL-SCI) is a biotechnology company which focuses on developing for immunotherapies for the treatment of cancer and other infectious diseases. The company carries out the research and development in finding techniques to activate the immune system. The company’s lead candidate is Multikine (leukocyte interleukin), an investigational immunotherapy against cancer and human papilloma virus (HPV). CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. The company has operations in Vienna, Virginia; and Baltimore, Maryland. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corporation Key Recent Developments

Feb 09, 2016: CEL-SCI Reports First Quarter Fiscal 2016 Financial Results
Dec 11, 2015: CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments
Nov 04, 2015: CEL-SCI’s Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
Aug 07, 2015: CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results
May 08, 2015: CEL-SCI Reports Second Quarter Fiscal Year 2015 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
CEL-SCI Corporation - Key Facts 6
CEL-SCI Corporation - Key Employees 7
CEL-SCI Corporation - Key Employee Biographies 8
CEL-SCI Corporation - Major Products and Services 9
CEL-SCI Corporation - Pharmaceutical Pipeline Products Data 10
CEL-SCI Corporation, Pipeline Products by Therapy Area 10
CEL-SCI Corporation, Pipeline Products by Development Phase 11
CEL-SCI Corporation - History 13
CEL-SCI Corporation - Company Statement 17
CEL-SCI Corporation - Locations And Subsidiaries 18
Head Office 18
Other Locations and Subsidiaries 18
Section 2 - Company Analysis 19
CEL-SCI Corporation - Business Description 19
CEL-SCI Corporation - Corporate Strategy 20
CEL-SCI Corporation - SWOT Analysis 21
SWOT Analysis - Overview 21
CEL-SCI Corporation - Strengths 21
Strength - Sturdy Research and Development Activities 21
Strength - Lead Product: Multikine 21
Strength - Innovative LEAPS Technology 21
CEL-SCI Corporation - Weaknesses 22
Weakness - Lack of Marketed Products 22
CEL-SCI Corporation - Opportunities 23
Opportunity - Orphan Drug Designation 23
Opportunity - Market Potential: Head and Neck Cancer 23
Opportunity - Collaborations 23
CEL-SCI Corporation - Threats 24
Threat - Competitive Pressures 24
Threat - Non-compliance of Government Regulations 24
Threat - Rapid Technological Changes 24
CEL-SCI Corporation - Key Competitors 25
Section 3 - Company Financial Ratios 26
Financial Ratios - Capital Market Ratios 26
Financial Ratios - Annual Ratios 27
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 - Company's Lifesciences Financial Deals and Alliances 31
CEL-SCI Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
CEL-SCI Corporation, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 32
CEL-SCI Corporation, Recent Deals Summary 33
Section 5 - Company's Recent Developments 34
Feb 09, 2016: CEL-SCI Reports First Quarter Fiscal 2016 Financial Results 34
Dec 11, 2015: CEL-SCI Reports Fiscal 2015 Financial Results and Clinical and Corporate Developments 35
Nov 04, 2015: CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization and Program Niche Analysis Plan by U.S. National Institutes of Health 36
Aug 07, 2015: CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results 37
May 08, 2015: CEL-SCI Reports Second Quarter Fiscal Year 2015 Financial Results 38
Feb 06, 2015: CEL-SCI Reports First Quarter 2015 Financial Results 39
Section 6 - Appendix 40
Methodology 40
Ratio Definitions 40
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
CEL-SCI Corporation, Key Facts 6
CEL-SCI Corporation, Key Employees 7
CEL-SCI Corporation, Key Employee Biographies 8
CEL-SCI Corporation, Major Products and Services 9
CEL-SCI Corporation, Number of Pipeline Products by Therapy Area 10
CEL-SCI Corporation, Number of Pipeline Products by Development Stage 11
CEL-SCI Corporation, Pipeline Products By Therapy Area and Development Phase 12
CEL-SCI Corporation, History 13
CEL-SCI Corporation, Subsidiaries 18
CEL-SCI Corporation, Key Competitors 25
CEL-SCI Corporation, Ratios based on current share price 26
CEL-SCI Corporation, Annual Ratios 27
CEL-SCI Corporation, Interim Ratios 29
CEL-SCI Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
CEL-SCI Corporation, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 32
CEL-SCI Corporation, Recent Deals Summary 33
Currency Codes 40
Capital Market Ratios 40
Equity Ratios 41
Profitability Ratios 41
Cost Ratios 42
Liquidity Ratios 42
Leverage Ratios 43
Efficiency Ratios 43

List of Figures
CEL-SCI Corporation, Pipeline Products by Therapy Area 10
CEL-SCI Corporation, Pipeline Products by Development Phase 11
CEL-SCI Corporation, Performance Chart (2011 - 2015) 28
CEL-SCI Corporation, Ratio Charts 30
CEL-SCI Corporation, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
CEL-SCI Corporation, Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.